SCHEMBL5022970

SCHEMBL5022970

COc1ccc(N(C(=O)c2ccc(Cl)cc2Cl)c2nc3ccc(NS(=O)(=O)c4ccccc4)cc3s2)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR27 Q9NS67 4/20 0.44
AVPR2 P30518 3/20 0.44
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
ALDH1A1 P00352 4/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NTRK1 P04629 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
PCTP Q9UKL6 1/20 0.40
STARD10 Q9Y365 1/20 0.40
KDM4E B2RXH2 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
PKM P14618 2/20 0.40
TSHR P16473 2/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5023079 0.93 ALDH1A1 (0.44) MAPTTP53ALDH1A1GAALMNA
SCHEMBL5023120 0.90 LMNA (0.40) MAPTFLT1FLT4KDRALDH1A1
SCHEMBL5022960 0.90 KDM4E (0.42) MAPTFLT1FLT4KDRALDH1A1
SCHEMBL5017118 0.89 NTRK1 (0.39) MAPTTP53GAALMNANTRK1
SCHEMBL14365370 0.88 DCLK1 (0.42) MAPTFLT1FLT4KDRGAA
SCHEMBL5016991 0.85 PPARG (0.40) MAPTFLT1FLT4KDRALDH1A1
SCHEMBL5022975 0.85 MEN1 (0.41) GPR27AVPR2MAPTTP53FLT1
SCHEMBL5016928 0.84 HSD17B10 (0.42) MAPTTP53ALDH1A1GAALMNA
SCHEMBL5016992 0.84 LMNA (0.51) MAPTTP53KDRALDH1A1LMNA
SCHEMBL5027178 0.84 KDM4E (0.40) MAPTFLT1FLT4KDRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638556-B1 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-04-02 EP claimed
US-7297707-B2 Benzothiazolyl derivatives HOFFMANN-LA ROCHE INC. (US) 2007-11-20 US claimed
US-20070021478-A1 Benzothiazolyl derivatives NETTEKOVEN MATTHIAS H 2007-01-25 US claimed
EP-1638556-A1 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-29 EP claimed
WO-2005000301-A1 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 WO claimed
US-20040266845-A1 Benzothiazolyl derivatives HOFFMANN-LA ROCHE INC. 2004-12-30 US claimed
EP-1638556-B1 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-04-02 EP disclosed
EP-1887425-A1 PHOTOCURING/THERMOSETTING RESIN COMPOSITION, CURING/SETTING PRODUCT THEREOF AND PRINTED WIRING BOARD OBTAINED USING THE SAME Taiyo Ink Manufacturing Co. Ltd (JP) 2008-02-13 EP disclosed
US-7297707-B2 Benzothiazolyl derivatives HOFFMANN-LA ROCHE INC. (US) 2007-11-20 US disclosed
US-7297707-B2 Benzothiazolyl derivatives HOFFMANN-LA ROCHE INC. (US) 2007-11-20 US disclosed
US-7297707-B2 Benzothiazolyl derivatives HOFFMANN-LA ROCHE INC. (US) 2007-11-20 US disclosed
US-20070021478-A1 Benzothiazolyl derivatives NETTEKOVEN MATTHIAS H 2007-01-25 US disclosed
US-20070021478-A1 Benzothiazolyl derivatives NETTEKOVEN MATTHIAS H 2007-01-25 US disclosed
US-20070021478-A1 Benzothiazolyl derivatives NETTEKOVEN MATTHIAS H 2007-01-25 US disclosed
EP-1638556-A1 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-29 EP disclosed
WO-2005000301-A1 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 WO disclosed
US-20040266845-A1 Benzothiazolyl derivatives HOFFMANN-LA ROCHE INC. 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021478-A1 Benzothiazolyl derivatives CNR1, CNR2, GPR119 GPR27 63/4885AVPR2 216/4885MAPT 3262/4885
US-20040266845-A1 Benzothiazolyl derivatives CNR1, CNR2, GPR119 GPR27 49/4885AVPR2 554/4885MAPT 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.